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Purpose: This study was designed to determine the relationship of cigarette 
smoking to the frequency and qualitative differences among KRAS mutations in 
lung adenocarcinomas from Korean patients. Materials and Methods: Detailed 
smoking histories were obtained from 200 consecutively enrolled patients with 
lung adenocarcinoma according to a standard protocol. EGFR (exons 18 to 21) 
and KRAS (codons 12/13) mutations were determined via direct-sequencing. Re-
sults: The incidence of KRAS mutations was 8% (16 of 200) in patients with lung 
adenocarcinoma. KRAS mutations were found in 5.8% (7 of 120) of tumors from 
never-smokers, 15% (6 of 40) from former-smokers, and 7.5% (3 of 40) from 
current-smokers. The frequency of KRAS mutations did not differ significantly 
according to smoking history (p=0.435). Never-smokers were significantly more 
likely than former or current smokers to have a transition mutation (G→A or 
C→T) rather than a transversion mutation (G→T or G→C) that is known to be 
smoking-related (p=0.011). In a Cox regression model, the adjusted hazard ratios 
for the risk of progression with epidermal growth factor receptor-tyrosine kinase 
inhibitors (EGFR-TKIs) were 0.24 (95% CI, 0.14-0.42; p<0.001) for the EGFR 
mutation and 1.27 (95% CI, 0.58-2.79; p=0.537) for the KRAS mutation. Conclu-
sion: Cigarette smoking did not influence the frequency of KRAS mutations in 
lung adenocarcinomas in Korean patients, but influenced qualitative differences 
in the KRAS mutations.
Key Words:   EGFR, KRAS, pulmonary adenocarcinoma, cigarette smoking, EG-
FR-tyrosine kinase inhibitors 
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and Survival Against Taxotere trial show no difference in 
overall survival (OS), progression-free survival (PFS), or 
response rate according to KRAS mutation status.10,26 
Few studies provide detailed correlations of KRAS muta-
tions with smoking history or treatment outcome following 
treatment with EGFR-TKIs. We, therefore, conducted this 
study to determine the relationship of cigarette smoking 
with the frequency and qualitative differences in KRAS mu-
tations in the lung adenocarcinomas of Korean patients. In 
addition, based on the concurrent mutational analysis, we 
evaluated the power of KRAS mutation status to predict 
treatment outcome with EGFR-TKIs in these patients.
MATERIALS AND METHODS
　　　
Study population and data collection
For this study, we enrolled 200 consecutive patients who 
had lung adenocarcinomas that were newly diagnosed and 
histologically confirmed between October 2007 and April 
2010 at the Yonsei Cancer Center  in Seoul, Korea and who 
were available for genetic analysis. The tumor histology was 
classified using the World Health Organization criteria.27 
Detailed smoking histories were prospectively obtained 
from these 200 patients with NSCLC according to a stan-
dard protocol that included the following questions:28 Have 
you smoked more than 100 cigarettes in your life? Are you 
currently smoking? How many years have you been a regu-
lar smoker; and on average, how many cigarettes did you 
smoke per day? The smoking questionnaire was adminis-
tered by a medical oncologist. Based on their smoking status, 
patients were categorized as never-smokers (<100 cigarettes 
in their lifetime), former-smokers (quit ≥1 year ago), or cur-
rent-smokers (quit <1 year ago). Pack-years of smoking were 
defined as [(average number of cigarettes per day/20)×years 
of smoking]. For all patients, medical records were reviewed 
to extract data based on their clinicopathological character-
istics. For patients with metastatic disease, we examined 
treatment regimens, overall response rates, and survival 
outcomes (PFS, OS). Clinical responses were assessed ev-
ery two cycles using computerized tomography and were 
classified using the Response Evaluation Criteria in Solid 
Tumor (RECIST version 1.0).29 PFS was measured from 
the first day of treatment with EGFR-TKI to progression or 
death, while OS was measured from the date of treatment 
with EGFR-TKI until the date of death. Patients were cen-
sored on July 31, 2010, if alive and progression-free. Patients 
INTRODUCTION
Lung cancer is one of the most common malignancies and is 
a leading cause of cancer-related mortality worldwide.1,2 Re-
cent development and approval of the epidermal growth fac-
tor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefi-
tinib and erlotinib, have significantly changed treatment 
outcomes in advanced non-small cell lung cancer (NSCLC).3 
Patients with adenocarcinoma who are of Asian origin, fe-
male gender, and with no history of smoking predict a strong 
response to EGFR-TKIs.4 In addition, molecular studies 
show a number of biomarkers associated with tumor sensi-
tivity to EGFR-TKIs.5-9 The presence of EGFR mutations, 
in particular, is associated with dramatic response to EGFR-
TKIs.5-7,9,10 On the other hand, somatic mutations of the 
KRAS oncogene may predict poor EGFR-TKI responsive-
ness.3,11-17
The RAS gene subfamily encodes a group of guanosine 
triphosphate-binding proteins, which are essential compo-
nents of the EGFR signaling cascade and play important 
roles in tumor pathogenesis.18,19 Single nucleotide muta-
tions in KRAS codons 12 and 13 compromise guanosine tri-
phosphatase (GTPase) activity.19,20 Such mutations may not 
only impair the intrinsic RAS GTPase activity, but also con-
fer resistance to GTPase-activating proteins. Consequently, 
RAS accumulates in its active GTP-bound state, resulting in 
constitutively activated RAS signaling.21 KRAS mutations 
are frequently observed in lung adenocarcinomas and may 
be smoking-related, while KRAS mutations are uncommon 
in squamous cell lung carcinomas and lung cancers in nev-
er-smokers.18,22,23 Interestingly, KRAS mutations occur more 
commonly in the lung tumors of Caucasian patients than in 
those of East Asians.21
Since KRAS mutations are common in NSCLC and ciga-
rette smoking is a frequent cause of NSCLC, KRAS muta-
tions are hypothesized to be related to tobacco exposure.18 
However, studies to test the association between cigarette 
smoking and KRAS mutation often lack detailed patient 
smoking histories and include relatively small numbers of 
never-smokers.  
The validity of the KRAS mutation as a predictive bio-
marker for lung cancer response to EGFR-TKIs remains un-
certain. Several reports support an association between the 
presence of KRAS mutation and poor response to EGFR-
TKIs.11-13,15,16,24,25 On the other hand, results of the IRESSA 
Non-Small-Cell-Lung Cancer Trials Evaluating Response 
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types were compared using the log-rank test. The adjusted 
hazard ratios (AHRs) for the risk of progression or death 
with treatment were compared between genotypes using a 
Cox regression model that included age, gender, smoking 
history, and performance status as independent variables. 
All p values were two-sided.
 
RESULTS
 
KRAS mutation and smoking history 
This entire cohort included 93 men and 107 women pa-
tients with a median age of 58 years (range: 28-84). All his-
tologic types were adenocarcinomas (Table 1). Based on 
smoking history, patients were classified into three groups: 
never-smokers (n=120, 60%), former smokers (n=40, 20%), 
and current smokers (n=40, 20%) (Table 1).
Among the 200 patients, 87 (43.5%) had EGFR muta-
tions and 16 (8%) had KRAS mutations in codons 12 (n= 
with no known date of death were censored on the date of 
their final follow-up. This study was approved by the Sev-
erance Hospital Institutional Review Board. All patients 
signed a written informed consent for genetic analysis.
       
EGFR and KRAS mutation analysis 
Nucleotide sequencing of the kinase domain of EGFR (ex-
ons 18 to 21) was performed using nested polymerase 
chain reaction amplification of the individual exons.17 The 
sequencing protocol has been previously described.13,28 
Specific mutations in KRAS exon 2 (codons 12 and 13) 
were identified from published data.13,28 
Statistical analysis
Data were summarized using standard descriptive statistics. 
Significant differences in the variables between genotypes 
were tested using the χ2 test, Fisher’s exact test, and t-tests 
where appropriate. The Kaplan-Meier method was used to 
estimate PFS and OS, and the differences between geno-
Table 1. Patient Characteristics 
Characteristic n KRAS mutation (%)      p value*
Age, yrs 0.188
    ≤60 112   6 (5.4)
    >60   88   10 (11.4)
Median age (range) 58 (28-84)   61.5 (44-74)
Sex 0.770
    Women 107   8 (7.5)
    Men   93   8 (8.6)
ECOG PS NS
    0-1 173 15 (8.6)
    2   22   1 (4.5)
Histology
    Adenocarcinoma 200 16 (8.0)
Stage‡ NS
    I-II   60   5 (8.3)
    III-IV 140 11 (7.9)
Smoking status  0.167†
    Never§ 120   7 (5.8)
    Former||   40     6 (15.0)
    Current¶   40   3 (7.5)
EGFR 0.002
    Wild-type 113   15 (13.3)
    Mutant   87   1 (1.1)
NS, not significant; EGFR, epidermal growth factor receptor; ECOG PS, Eastern Cooperative Oncology Group Performance Status. 
*According to Pearson’s χ2 or Fisher’s exact test.
†Never versus others.
‡Stage at the time of initial diagnosis.
§Never-smokers had smoked fewer than 100 cigarettes.
||Former smokers had previously smoked cigarettes but quit smoking more than one year prior to diagnosis of lung cancer.
¶Current smokers had quit less than one year ago.
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Supplementary Table 1. Summarized Treatment Outcome with EGFR-TKI of Individual Patients with Metastatic Lung Adeno-
carcinoma (n=96)
Patient 
no.
Age Sex Stage EGFR mutation
KRAS 
mutation
Smoking 
status
EGFR 
TKI
Best 
response
PFS* 
(months)
OS† 
(months)
Alive
  1 61 M IV Negative Gly12Ser Former G PD   1.0   5.9 No
  2 67 M IV Negative Gly12Val Former G PD   1.3   1.3 No
  3 50 F IV Negative Gly12Ser Never G PD   1.0 15.9 No
  4 58 M IIIB Negative Gly12Cys Former E PD   1.0   1.1 No
  5 44 M IIIB Negative Gly12Val Current E PR 32.0 45.8 Yes
  6 70 F IIIB Negative Gly12Asp Never G SD   7.0   9.3 No
  7 61 F IIIB Negative Gly12Asp Never E SD   1.6 25.6 No
  8 58 F IB Negative Gly>Asp Never G PD   2.2   9.3 No
  9 56 M IV
20 (T790M)/
21 (L858R)
Negative Never G PD   1.0   2.6 Yes
10 61 M IV
His773Tyr/
21 (L858R)
Negative Former G PD   2.0   5.9 No
11 69 F IV 21 (L858R) Negative Never G PD   0.3   0.4 No
12 46 M IV 19 (del) Negative Never G PD   0.9   1.1 No
13 59 M IV 19 (del) Negative Former G PR   1.5   1.5 Yes
14 68 F IV 21 (L858R) Negative Never G PR 14.0 14.0 Yes
15 48 F IV 21 (L858R) Negative Never G PR 46.0 47.5 Yes
16 54 F IV 19 (del) Negative Never G PR 17.0 22.5 Yes
17 66 M IV 21 (L858R) Negative Former E PR 10.8 13.3 No
18 47 F IV 21 (L858R) Negative Never E PR 14.1 22.3 Yes
19 67 F IV 19 (del) Negative Never E PR   6.5   8.3 No
20 68 F IV 19 (del) Negative Never E PR   8.0 13.8 No
21 52 M IV 21 (L858R) Negative Current E PR   7.0 11.0 No
22 50 M IV 19 (del) Negative Never G PR 12.3 26.8 No
23 58 F IV 19 (del) Negative Never G PR 23.4 33.3 No
24 46 F IV 19 (del) Negative Never G SD 10.5 10.5 Yes
25 64 M IV 21 (L858R) Negative Former G SD   9.6   9.7 Yes
26 50 M IV 21 (L858R) Negative Current G SD   3.0   3.0 Yes
27 58 F IV 21 (L858R) Negative Never G SD 22.5 22.5 Yes
28 42 F IV 21 (L858R) Negative Never G SD   3.2   3.2 Yes
29 41 M IV 19 (del) Negative Former E SD   1.3   1.3 Yes
30 67 F IV 19 (del) Negative Never G SD 10.0 12.6 No
31 64 F IV 19 (del) Negative Current G SD   1.9   2.6 No
32 54 F IV 19 (del) Negative Never E SD 10.3 22.5 No
33 51 M IV 19 (del) Negative Former E SD   8.7 25.2 Yes
34 47 F IV 21 (L858R) Negative Never G SD   8.5 10.3 No
35 58 M IV 19 (del) Negative Current G SD 14.1 34.1 No
36 43 F IV 19 (del) Negative Never G SD 23.9 52.5 Yes
37 48 F IV 21 (L858R) Negative Never G SD 13.7 36.4 No
38 48 F IV 21 (L858R) Negative Never G SD 13.7 36.4 No
39 56 F IV 19 (del) Negative Never G SD 19.3 24.8 No
40 61 F IV 19 (del) Negative Never G SD 13.6 13.6 No
41 37 F IIIB 19 (del) Negative Never G PR   8.7 30.7 No
42 50 F IIIB 19 (del) Negative Never G SD   3.2 16.2 No
43 73 M IIB 19 (del) Negative Never G SD   9.1   9.2 Yes
44 30 M IIA 19 (del) Negative Former G PD 19.7 34.5 Yes
45 71 M IB 19 (del) Negative Former E SD 11.2 12.0 Yes
46 54 M IB 21 (L858R) Negative Never G SD 34.5 48.6 Yes
47 65 F IA 19 (del) Negative Never E PR 11.4 11.4 Yes
48 44 F IA 21 (L858R) Negative Never E SD 12.8 41.5 No
Smoking and KRAS Mutation in NSCLC
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Supplementary Table 1. Continued
Patient 
no.
Age Sex Stage EGFR mutation
KRAS 
mutation
Smoking 
status
EGFR 
TKI
Best 
response
PFS* 
(months)
OS† 
(months)
Alive
49 60 F IA 19 (del) Negative Never G SD   7.7 13.6 No
50 45 F IV Negative Negative Never G PD   0.9   2.7 Yes
51 53 M IV Negative Negative Current G PD   0.5   0.6 No
52 39 M IV Negative Negative Never E PD   1.1   1.1 No
53 70 M IV Negative Negative Current G PD   0.9   2.1 No
54 56 M IV Negative Negative Current E PD   1.1   3.9 No
55 62 M IV Negative Negative Current E PD   1.0 13.8 No
56 70 M IV Negative Negative Former G PD   0.2   1.0 No
57 57 M IV Negative Negative Current E PD   0.4   0.5 No
58 50 F IV Negative Negative Never E PD   0.9   0.9 No
59 60 F IV Negative Negative Never E PD   1.3   5.1 No
60 45 M IV Negative Negative Former E PD   0.2   0.3 No
61 56 F IV Negative Negative Never E PD   0.6 28.4 Yes
62 30 F IV Negative Negative Never E PD   2.1   4.8 No
63 37 F IV Negative Negative Never G PD   0.6   4.0 No
64 55 F IV Negative Negative Never G PD   3.7   5.8 No
65 74 M IV Negative Negative Current G PD   1.0   3.9 No
66 68 M IV Negative Negative Former G PD   2.1   4.8 No
67 65 M IV Negative Negative Former E PD   1.8   4.2 No
68 55 M IV Negative Negative Former G PD   1.0 12.5 No
69 75 M IV Negative Negative Current G PR 22.6 41.3 No
70 54 M IV Negative Negative Current E PR   1.8 15.5 No
71 73 F IV Negative Negative Never E PR   0.4   0.6 No
72 50 M IV Negative Negative Never G PR   7.2 18.0 No
73 54 M IV Negative Negative Former E SD   0.9   1.0 Yes
74 56 F IV Negative Negative Never G SD   2.6   2.7 Yes
75 50 M IV Negative Negative Current G SD   7.4   7.9 Yes
76 72 M IV Negative Negative Never E SD   6.9 14.9 No
77 58 F IV Negative Negative Former E SD   1.2   8.3 No
78 35 F IV Negative Negative Never G SD   6.4 17.6 No
79 75 M IIIB Negative Negative Former G PD   1.0   4.0 Yes
80 36 M IIIB Negative Negative Current E PD   3.0 10.8 No
81 67 M IIIB Negative Negative Former G PD   3.1   8.0 No
82 52 F IIIB Negative Negative Never G PD   1.2 12.6 No
83 67 F IIIB Negative Negative Never G SD   4.5 21.0 Yes
84 54 F IIIB Negative Negative Never G SD   3.3 11.9 No
85 64 M IIIB negative Negative Current E SD   4.5 39.8 Yes
86 59 F IIIA Negative Negative Never G PD   1.0   6.4 No
87 59 F IIIA Negative Negative Never G PR   3.9   5.1 No
88 36 F IIIA Negative Negative Never G SD 14.0 14.1 Yes
89 52 F IIIA Negative Negative Never E SD   8.0 14.2 Yes
90 57 M IIIA Negative Negative Never G SD   2.4   2.6 No
91 51 F IIIA Negative Negative Never G SD   6.6 35.6 No
92 56 M IIIA Negative Negative Never G SD   4.3 36.1 No
93 54 M IIB Negative Negative Never G PD   2.0   2.2 No
94 66 M IB Negative Negative Former E PD   0.3   0.5 No
95 68 M IB Negative Negative Former G SD   5.7   8.5 No
96 52 M IB Negative Negative Current G SD   2.1 12.0 No
PFS, progression free survival; OS, overall survival; PR, partial response; SD, stable disease; PD, progressive disease; G, gefitinib; E, erolotinib; EGFR, epi-
derman growth factor receptor; TKI, tyrosine kinase inhibitor.
*PFS was measured from the first day of treatment with EGFR-TKI to the progression or death.
†OS was measured from the date of treatment with EGFR-TKI until the date of death.
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tory (Mantel-Haenszel χ2 test, p= 0.435). KRAS mutations 
were identified in 5.8% (7/120) of never-smokers, 15% 
(6/40) of former smokers, and 7.5% (3/40) of current smok-
ers (Fig. 1). Moreover, age at first cigarette, total pack-years, 
total smoke-years, and smoke free-years were not correlat-
ed with KRAS mutations (Supplementary Fig. 1).
Never-smokers were significantly more likely than for-
mer- or current smokers to have a transition mutation (sub-
stitution of a purine for a purine, e.g., G→A or a pyrimidine 
for a pyrimidine, C→T) than a transversion mutation (sub-
stitution of a purine for a pyrimidine or conversely, G→T 
or G→C), which are known to be smoking-related (p= 
0.011) (Table 2).
Treatment outcome with EGFR tyrosine kinase 
inhibitors 
Of 153 patients with advanced lung adenocarcinoma, 97 re-
ceived EGFR-TKIs (Supplementary Table 1). Among 
them, one patient had both EGFR and KRAS mutations de-
tected and received a combination treatment of erlotinib 
and sorafenib in a clinical trial. This patient showed a par-
tial response (PR) lasting more than 15 months. Among the 
41 patients with EGFR mutations, 25 (61.0%) showed a 
clinical response to EGFR-TKIs, 11 (26.8%) had stable dis-
ease (SD), and 5 patients (12.2%) had progressive disease 
(PD). In the 8 patients with KRAS mutations, one (12.5%) 
showed a clinical response to EGFR-TKIs, 2 (25.0%) had 
SD, and 5 (62.5%) had PD on EGFR-TKIs (Table 3). In 47 
patients with wild-type EGFR and KRAS (WT/WT), 5 
(10.6%) had PR, 16 patients (34.0%) had SD, and 26 pa-
tients (55.3%) had PD on EGFR-TKIs. As a group, patients 
with KRAS mutations had a significantly poorer clinical re-
sponse to EGFR-TKIs than those who had EGFR muta-
tions (12.5% vs. 61.0%, p=0.004), but did not differ in clin-
ical response from those with WT/WT (10.6% vs.12.5%, 
p=0.876).
At the time of analysis, the median follow-up duration of 
14) or 13 (n=2). One patient had both an EGFR mutation 
(exon 19, del 2235-2249) and a KRAS mutation (Gly12Cys, 
GGT→TGT). Patients with a KRAS mutation and those with 
wild-type KRAS (WT) did not differ in baseline characteris-
tics including age, gender, Eastern Cooperative Oncology 
Group (ECOG) performance status, histology, stage at initial 
diagnosis, and smoking history (Table 1). Presence of the 
KRAS mutation was not significantly related to smoking his-
Fig. 1. Frequency of KRAS mutation according to smoking history.
Supplementary Fig. 1. Comparison of median values for various factors re-
garding cigarette-smoking according to KRAS mutation status. The num-
ber of y-axis represents the number according to the variables in x-axis 
(age at first cigarette, pack-years, smoke years, cigarettes per day, and 
smoke free year), respectively.
Table 2. Types of KRAS Mutations According to Smoking History 
Type of KRAS mutation Nucleotide Never-smoker Ever-smoker p value
Transition 0.011*
    G13D  GGC→GAC 0 1
    G12D GGT→GAT 4 1
    G12S GGT→AGT 2 1
Transversion
    G12C GGT→TGT 1 2
    G12V GGT→GTT 0 3
    G13C GGC→TGC 0 1
*Fisher’s exact test, transition versus transversion.
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al outcome included 96 patients. 
The three genotypes according to the presence of EGFR 
or KRAS mutation showed significant differences in median 
OS with EGFR-TKI treatment (26.7 months for the EGFR 
mutant, 8.2 months for WT/WT, and 9.2 months for the 
KRAS mutant, p=0.001) (Fig. 2A). In a Cox regression 
model adjusted for age, gender, smoking history and perfor-
mance status, the AHRs for OS were 0.453 (95% CI, 0.260-
patients with advanced lung adenocarcinoma was 17.4 
months. At the time of analysis, 103 (51.5%) of the 200 pa-
tients were still alive. In this survival outcome analysis, we 
excluded one patient who had both EGFR and KRAS muta-
tions and who was treated with erlotinib/sorafenib because 
this dual inhibition of the EGFR and vascular endothelial 
growth factor (VEGF) pathways could influence survival 
outcome and cause a bias. Thus, the final analysis of surviv-
Fig. 2. Kaplan-Meier survival plots for patients with three tumor genotypes in metastatic lung adenocarcinoma treated with EGFR tyrosine kinase inhibitors 
(TKIs): EGFR mutation (n=41), KRAS mutation (n=8), and WT/WT (n=47). (A) Median OS with EGFR TKI treatment (26.7 months for EGFR mutation vs. 8.2 
months for WT/WT vs. 9.2 months for KRAS mutant, p=0.001). (B) Median PFS (12.8 months for EGFR mutation vs. 1.2 months for KRAS mutation vs. 1.9 
months for WT/WT, p<0.001). 
Table 3. Characteristics and TKI Responses of Nine Lung Cancer Patients with KRAS Mutations 
No. Sex
Smoking 
status
Type of KRAS 
mutation
EGFR 
mutation
Type of 
TKI
Best 
response
PFS* 
(months)
OS†
(months)
1 M Former Transition No G PD 1.0   5.9
2 M Former Transversion No G PD 1.3   1.3
3 F Never Transition No G PD 1.0 15.9
4 M Former Transversion No E PD 1.0   1.1
5 M Current Transversion No E PR 32.0 45.8
6 F Never Transition No G SD 7.0   9.3
7 F Never Transition No G SD 1.6 25.6
8 F Never Transition No G PD 2.2   9.3
TKI, tyrosine kinase inhibitor; PFS, progression-free survival; OS, overall survival; PR, partial response; SD, stable disease; PD, progressive disease; G, gefi-
tinib; E, erlotinib; EGFR, epidermal growth factor receptor.
*PFS was measured from the first day of treatment with EGFR-TKI to the date of progression or death.
†OS was measured from the date of treatment with EGFR-TKI until the date of death.
Table 4. Prognostic Significance of Gene Mutations in Metastatic Lung Adenocarcinoma Treated with EGFR TKIs
Genotype
PFS for EGFR TKIs OS*
No. of mutant/ 
wild-type
AHR† (95% CI) p value
No. of mutant/ 
wild-type
AHR† (95% CI) p value
EGFR (+ v -) 41/55 0.246 (0.144-0.421) <0.001 41/55 0.453 (0.260-0.787) 0.005
KRAS (+ v -)   8/88 1.278 (0.586-2.790)   0.537   8/88 1.274 (0.571-2.845) 0.554
EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; AHR, adjusted hazard ratio; 95% CI, 95% confidence interval; OS, overall survival; 
PFS, progression-free survival. 
*Overall survival was measured from the initiation of EGFR-TKIs until death. 
†Adjusted for age, gender, smoking history and performance status
A B
0 0
20 20
40 40
60 60
80 80
100 100
%
 O
ve
ra
ll s
ur
viv
al
%
 P
ro
gr
es
sio
n 
fre
e 
su
rv
iva
l
0 024 2448 4812 1236 3660
Time (months) Time (months)
  KRAS mutant  
  EGFR mutant     
  WTNVT 
  KRAS mutant  
  EGFR mutant     
  WTNVT 
p=0.001 p<0.001
Hye Ryun Kim, et al.
Yonsei Med J   http://www.eymj.org   Volume 54   Number 4   July 2013872
been established.22,23 However, careful scrutiny of these 
studies reveals that they included relatively small numbers 
of never-smokers and neglected to present detailed smok-
ing histories. In a study of lung adenocarcinomas from al-
most 500 patients (17% never-smokers), Riely, et al.28 re-
ported the presence of a KRAS mutation in 15% of tumors 
from never-smokers compared to 22% in the group overall, 
showing that smoking history does not clearly predict KRAS 
mutation status. In contrast, data from a recent meta-analy-
sis show a significantly higher KRAS mutation frequency 
among current- or former smokers compared to that of nev-
er-smokers (26% vs. 6%, p<0.01).3 In our study, careful in-
terpretation will be required because the lack of statistical 
significance might be caused by insufficient sample size. 
The association of KRAS mutation (i.e., presence of the mu-
tation in the tumor) with smoking history, which includes 
cumulative smoking dose, age at first exposure, smoke-free 
years, and other factors, awaits further observation and anal-
ysis of large populations with detailed smoking histories. 
Importantly, KRAS mutations observed in never-smokers 
are significantly more likely to be transition mutations than 
those in current- and former smokers, which is consistent 
with previous data.28 Similarly, transition mutations in TP53 
are more common in never-smoker patients than transver-
sions. This prevalence for transversions in TP53 may identify 
a molecular signature for the action of specific carcinogen(s) 
in cigarette smoke.28,36 Thus, the qualitative differences in 
KRAS mutations in lung tumors from never-smokers may 
be related to intrinsic tumorigenesis rather than to exposure 
to extrinsic carcinogens such as second-hand tobacco smoke. 
The role of KRAS mutation in predicting survival with EG-
FR-TKIs treatment remains unclear.3,19 Although most stud-
ies show that a KRAS mutation predicts a poor response to 
EGFR-TKIs, these data do not strongly support an associa-
tion between KRAS mutation and survival outcome because 
the reported treatment outcomes are not survival outcome 
such as OS or PFS, but response rate.3,11,13,15-17 Additionally, 
because EGFR and KRAS mutations are mutually exclusive, 
patients with KRAS mutations do not harbor EGFR muta-
tions, whereas those with wild-type KRAS may potentially 
harbor EGFR mutations. Given the extreme sensitivity of 
EGFR mutant tumors to EGFR-TKIs, even a small propor-
tion of patients with EGFR mutation in a cohort with KRAS 
wild-type tumors could confound or bias the association be-
tween mutation type and treatment outcome with EGFR-
TKIs. To clarify the prognostic significance of KRAS muta-
tion for these treatment outcomes, concurrent mutational 
0.787; p=0.005) for the EGFR mutant and 1.274 (95% CI, 
0.571-2.842, p=0.554) for the KRAS mutant (Table 4). 
The three genotypes differed significantly in median PFS 
(12.8 months for the EGFR mutant vs. 1.2 months for the 
KRAS mutant vs. 1.9 months for WT/WT, p<0.001). In a 
pair-wise comparison, the EGFR mutant showed a signifi-
cantly longer median PFS than did the KRAS mutant or the 
WT/WT. The KRAS mutant and WT/WT did not differ sig-
nificantly (p=0.588) (Fig. 2B). In a Cox regression model 
adjusted for age, gender, smoking history and performance 
status, the AHRs for the risk of disease progression with 
EGFR-TKI treatment was 0.246 (95% CI, 0.144-0.421; p< 
0.001) for the EGFR mutation and 1.278 (95% CI, 0.586-
2.790; p=0.537) for the KRAS mutation (Table 4). These 
data identified the EGFR mutation as an independent posi-
tive predictive factor for treatment outcome with EGFR-
TKIs and showed that the KRAS mutation did not predict 
treatment outcome with EGFR-TKIs. The outcome is total-
ly driven by presence or absence of EGFR mutation.
DISCUSSION
To our best knowledge, this is the largest comprehensive 
analysis of the KRAS mutation and its association with 
smoking history performed to date in East Asian patients 
with lung adenocarcinomas. The main finding of our study 
was a lower incidence of the KRAS mutation in these tumors 
among our Korean study group compared to that reported 
for Western populations. Interestingly, cigarette smoking did 
not influence the frequency of KRAS mutation, but rather 
the type of KRAS mutation; and KRAS mutation did not in-
dependently predict outcome of EGFR-TKI therapy.  
The low frequency of KRAS mutation in our study (8%, 
16 of 200) is in good agreement with previous findings of 
KRAS mutation of less than 10% in East Asian patients with 
lung adenocarcinoma, compared with the recorded 30% or 
more among Caucasian patients.24,30-35 This difference 
might be explained by ethnic and environmental factors, in 
addition to reported differences in gender and smoking sta-
tus distributions.34
The frequency of KRAS mutation did not differ according 
to smoking status in our study. In addition, the specific 
characteristics of smoking such as cumulative dose (pack-
years), age at first exposure, and smoke-free years did not 
correlate with KRAS mutation frequency. A strong associa-
tion between KRAS mutation and cigarette smoking has 
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